Online inquiry

IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15376MR)

This product GTTS-WQ15376MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15376MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14497MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ14695MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SCT-400
GTTS-WQ2444MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ13336MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ2913MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ9451MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ5077MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ8257MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HLX10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW